SavedAdd your journal

Journals / ODÜ Tıp Dergisi / 2026 / Cilt: 13 Sayı: 2

Apixaban Use in the Management of Cerebral Venous Sinus Thrombosis: Two Cases with Warfarin Resistance and Labile INR

Serebral Venöz Sinüs Trombozu Yönetiminde Apiksaban Kullanımı: Varfarin Direnci ve Labil INR İzlenen İki Olgu

Didem Erol(ORDU ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-8349-4063
Gökçe Yüce Onur(ORDU ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7340-8187
Pages
145–150
Publication Date
2026-10-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Thanks to its predictable pharmacokinetic advantages, apixaban may increase patient compliance and clinical success by eliminating the requirement for routine monitoring.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Cerebral venous sinus thrombosis (CVST) treatment primarily relies on effective anticoagulation; following the acute phase, the standard option during the maintenance period is typically vitamin K antagonists (VKA).
📊
Key Findings & Data:Case Presentation: With apixaban (5 mg bid) treatment, complete clinical recovery was achieved in both patients, and total recanalization was detected on magnetic resonance venography (MRV).
💡
Conclusion & Impact:Conclusion: Thanks to its predictable pharmacokinetic advantages, apixaban may increase patient compliance and clinical success by eliminating the requirement for routine monitoring.
🔬Design:Olgu Sunumu
📍Scope:Comprehensive Sample
⚙️Variables:Serebral venöz sinüs trombozu · apiksaban · varfarin direnci

Abstract

Background: Cerebral venous sinus thrombosis (CVST) treatment primarily relies on effective anticoagulation; following the acute phase, the standard option during the maintenance period is typically vitamin K antagonists (VKA). However, warfarin resistance or a labile international normalized ratio (INR) course are critical barriers that limit an effective treatment process. In this report, two CVST cases where therapeutic targets could not be reached with standard anticoagulant therapy and the experience with apixaban use are presented. Case Presentation: With apixaban (5 mg bid) treatment, complete clinical recovery was achieved in both patients, and total recanalization was detected on magnetic resonance venography (MRV). No recurrent thrombosis or bleeding complications developed during the follow-up period. These cases support that apixaban is an effective and safe alternative in selected CVST cases. Conclusion: Thanks to its predictable pharmacokinetic advantages, apixaban may increase patient compliance and clinical success by eliminating the requirement for routine monitoring.

Özet

Arka Plan: Serebral venöz sinüs trombozu (SVST) tedavisinde temel strateji etkin antikoagülasyondur; akut fazı takiben idame dönemindeki standart seçenek genellikle vitamin K antagonistleridir (VKA). Ancak varfarin direnci veya labil uluslararası düzeltilmiş oran (INR) seyri, etkin tedavi sürecini kısıtlayan kritik engellerdir. Bu sunumda; standart antikoagülan tedavi ile terapötik hedeflere ulaşılamayan iki SVST olgusu ve apiksaban kullanım deneyimi sunulmuştur. Olgu Sunumu: Apiksaban (5 mg 2x1) tedavisiyle her iki hastada tam klinik iyileşme sağlanmış ve manyetik rezonans venografide (MRV) tam rekanalizasyon saptanmıştır. İzlem sürecinde nüks tromboz veya kanama komplikasyonu gelişmemiştir. Bu olgular, seçilmiş SVST vakalarında apiksabanın etkili ve güvenli bir alternatif olduğunu desteklemektedir. Sonuç: Apiksaban, öngörülebilir farmakokinetik avantajları sayesinde rutin izlem gereksinimini ortadan kaldırarak hasta uyumunu ve klinik başarıyı artırabilir.

🔖

Cite This Article

Erol, D., Onur, G. Y. (2026). Apixaban Use in the Management of Cerebral Venous Sinus Thrombosis: Two Cases with Warfarin Resistance and Labile INR. ODÜ Tıp Dergisi, Cilt: 13 Sayı: 2, 145–150. https://doi.org/10.56941/odutip.1971567

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Massaro A, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670.
  2. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158-1192.
  3. Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur Stroke J. 2017;2(3):195-221.
  4. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692-1711.
  5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
  6. Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amarjyoti N, et al. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022;53(3):728-738.
  7. Field TS, Fragata I. Current Management of Cerebral Venous Thrombosis. Stroke. 2026;57(1). Epub ahead of print.
  8. Miyakis S, Lockshin MD, Atsumi T, Tincani A, Giouvanoudi EK, Krilis SA, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
  9. Simaan N, Metanis I, Honig A, Hallevi H, Filioglo A, Mendel R, et al. Efficacy and safety of apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study. Front Neurol.2024;15:1404099.
  10. Khialani D, le Cessie S, Lijfering WM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. Br J Haematol. 2020;191(1):90-97.
  11. Waseem MH, Abideen ZU, Shoaib A, Rehman N, Osama M, Sajid B, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis of 4,929 Patients. Clin Appl Thromb Hemost.2025;31:10760296251405417.